Makena® (hydroxyprogesterone caproate) – New formulation
February 14, 2018 - AMAG Pharmaceuticals announced the FDA approval of Makena (hydroxyprogesterone caproate) subcutaneous (SC) injection, to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Top